Study Graphic

You may be eligible if:
• You are a healthy male or female (unable to bear children) 18-55 years of age.
• You are able to meet all eligibility criteria.
• You are able to comply with all study visits.

Study Number: A3921262

Be compensated for your time: up to $2600.00 for completion of the study

The Pfizer New Haven Clinical Research Unit is conducting a study of a marketed drug used to treat people with rheumatoid arthritis (RA), ulcerative colitis (UC), and psoriatic arthritis (PsA). RA is a disorder of the immune system that causes inflammation in the joints (hands, feet, wrists). It can cause joint damage, pain, and deformities to the affected joints. UC is inflammation of the large intestine (colon and rectum) and includes ulcers (sores) in the innermost lining of the large intestine. PsA is also a disorder of the immune system that causes arthritis. Most people who develop this condition also have psoriasis (raised red patches on the skin). It has been approved in the United States (US) by the Food and Drug Administration (FDA), and in some other countries, for the treatment of RA. Two different formulations have been approved: the immediate release (IR) and extended release (XR) tablets.

This study involves:
You will be in this study up to about 43 days. This does not include the time between screening and dosing, which can be up to 28 days.

This study involves:

• 4 dosing periods (during 1 continuous admission)
• 8 overnight stays
• 1 follow-up phone call (between 28 and 35 days after the last dose of study drug)

A3921262 Revised IRB approved ICD 23Jun2020